Skip to main content
ModernaIn development

Moderna Plan to Test mRNA COVID and Flu Vaccines on 410,000 Elderly a ‘Catastrophe in the Making,’ Critic Says - Science, Public Health Policy and the Law

Source: Autobound Signal API · 106 signals tracked for Moderna · updated

Get Moderna's live signals in Claude or ChatGPT, or by API

AskWhat changed at Moderna this week? Use Autobound signals for modernatx.com.

What happened

Moderna is conducting the DAN-COMBO clinical trial to evaluate its mRNA-1083 combination COVID-19 and flu vaccine.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

By Michael Nevradakis, Ph.D. Scientists and physicians critical of mRNA vaccines warn that a new clinical trial for Moderna's combination mRNA COVID-19 and flu vaccine could expose hundreds of thousands of older adults to serious health risks, including cardiac problems, blood clots and death. The warnings stem from concerns about adverse event data associated with the two vaccines used in the trial and the trial's methodology. The " DAN-COMBO " study will compare Moderna's mRNA-1083 combination shot with two separate shots: Moderna's Spikevax COVID-19 vaccine and its mRNA-1010 high-dose flu vaccine . The large-scale trial, which Moderna plans to conduct in Denmark and Spain, seeks to enroll 410,000 healthy Danish adults age 65 and older. It's scheduled to launch this month and run through next year's cold-and-flu season. The trial could involve up to one-third of Denmark's 65-and-over population, according to an analysis by the World Council for Health Scandinavia. According to the DAN-COMBO research team, the study is needed because "knowledge is still lacking" about the relative efficacy of a combination COVID-19 and flu vaccine compared with two standalone shots. But scientists and physicians critical of mRNA vaccines have warned that Moderna's new clinical trial could expose older adults to serious adverse events. Brian Hooker, Ph.D., chief scientific officer of...

Keep reading with a free account

The rest of this article, and every signal for Moderna, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
mRNA-1083
Location
Denmark

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • general technology
  • future tech

Extraction

Confidence
95%
Detected
Oct 28, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/4708587b-d63b-e1ac-f9e9-ef0238ceff12 returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "4708587b-d63b-e1ac-f9e9-ef0238ceff12",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-28T17:54:45+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "url": "https://publichealthpolicyjournal.com/moderna-plan-to-test-mrna-covid-and-flu-vaccines-on-410000-elderly-a-catastrophe-in-the-making-critic-says/",
    "title": "Moderna Plan to Test mRNA COVID and Flu Vaccines on 410,000 Elderly a ‘Catastrophe in the Making,’ Critic Says - Science, Public Health Policy and the Law",
    "excerpt": "By Michael Nevradakis, Ph.D. Scientists and physicians critical of mRNA vaccines warn that a new clinical trial for Moderna’s combination mRNA COVID-19 and flu vaccine could expose hundreds of thousands of older adults to serious health risks, including cardiac problems, blood clots and death. The warnings stem from concerns about adverse event data associated with the two vaccines used in the trial and the trial’s methodology. The “ DAN-COMBO ” study will compare Moderna’s mRNA-1083 combination shot with two separate shots: Moderna’s Spikevax COVID-19 vaccine and its mRNA-1010 high-dose flu vaccine . The large-scale trial, which Moderna plans to conduct in Denmark and Spain, seeks to enroll 410,000 healthy Danish adults age 65 and older. It’s scheduled to launch this month and run through next year’s cold-and-flu season. The trial could involve up to one-third of Denmark’s 65-and-over population, according to an analysis by the World Council for Health Scandinavia . According to the DAN-COMBO research team, the study is needed because “knowledge is still lacking” about the relative efficacy of a combination COVID-19 and flu vaccine compared with two standalone shots. But scientists and physicians critical of mRNA vaccines have warned that Moderna’s new clinical trial could expose older adults to serious adverse events. Brian Hooker, Ph.D., chief scientific officer of...",
    "product": "mRNA-1083",
    "summary": "Moderna is conducting the DAN-COMBO clinical trial to evaluate its mRNA-1083 combination COVID-19 and flu vaccine.",
    "location": "Denmark",
    "planning": true,
    "image_url": "https://i0.wp.com/publichealthpolicyjournal.com/wp-content/uploads/2024/03/WSES-logo-800.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "mRNA-1083",
      "full_text": "mRNA-1083 combination shot",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology",
      "future_tech"
    ],
    "published_at": "2026-10-28T17:54:45Z",
    "location_data": [
      {
        "region": "Northern Europe",
        "country": "Denmark",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The “ DAN-COMBO ” study will compare Moderna’s mRNA-1083 combination shot with two separate shots: Moderna’s Spikevax COVID-19 vaccine and its mRNA-1010 high-dose flu vaccine ."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.